AZD2184: A radioligand for sensitive detection of β-amyloid deposits

Journal of Neurochemistry

Volumn 108, Issue 5, 2009, Pages 1177-1186

  Johnson, Allan E ^a   Jeppsson, Fredrik ^a   Sandell, Johan ^a   Wensbo, David ^a   Neelissen, Jan A M ^a   Juréus, Anders ^a   Ström, Peter ^a   Norman, Henrietta ^a   Farde, Lars ^a,b   Svensson, Samuel P S ^a  

^a ASTRAZENECA R AND D   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

amyloid; Alzheimers; Imaging; Plaques; Positron emisson tomography

Indexed keywords

2 (3 FLUORO 4 METHYLAMINO PHENYL) BENZOTHIAZOL 6 OL H 3; 2 [6 (METHYLAMINO)PYRIDIN 3 YL] 1,3 BENZOTHIZOL 6 OL H 3; AMYLOID; AMYLOID BETA PROTEIN[1-40]; AZD 2184; PRESENILIN 1; RADIOLIGAND; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; AUTORADIOGRAPHY; CONTROLLED STUDY; DRUG CLEARANCE; DRUG HALF LIFE; DRUG PROTEIN BINDING; HUMAN; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PREFRONTAL CORTEX; PRIORITY JOURNAL; RAT; TRANSGENIC MOUSE; WHITE MATTER;

ALZHEIMER DISEASE; AMINOPYRIDINES; AMYLOID BETA-PROTEIN; AMYLOID BETA-PROTEIN PRECURSOR; ANILINE COMPOUNDS; ANIMALS; AUTORADIOGRAPHY; BENZOTHIAZOLES; BRAIN; CARBON RADIOISOTOPES; COMPETITIVE BIDDING; HUMANS; MALE; MICE; MICE, TRANSGENIC; MUTATION; POSITRON-EMISSION TOMOGRAPHY; PRESENILIN-1; PROTEIN BINDING; RADIOLIGAND ASSAY; RATS; RATS, SPRAGUE-DAWLEY; SENILE PLAQUES; THIAZOLES; TRITIUM;

MUS; RATTUS;

EID: 59449097248     PISSN: 00223042     EISSN: 14714159     Source Type: Journal    
DOI: 10.1111/j.1471-4159.2008.05861.x     Document Type: Article

References (24)

1. 18F]fluorobenzothiazole as potentioal amyloid imaging agent. J. Label. Compd. Radiopharm. 51, 137 145.
2. Braak H. Braak E. (1991) Neuropathological staging of Alzheimer-related changes. Acta Neuropathol. (Berl.) 82, 239 259.
3. Cai L., Innis R. B. Pike V. W. (2007) Radioligand development for PET imaging of β-amyloid (Aβ)-current status. Curr. Med. Chem. 14, 19 52.
4. Dubois B., Feldman H. H., Jacova C. et al. (2007) Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. Lancet Neurol. 6, 734 746.
5. Duff K., Eckman C., Zehr C. et al. (1996) Increased amyloid-beta42(43) in brains of mice expressing mutant presenilin. Nature 383, 710 713.
6. Forsberg A., Engler H., Almkvist O., Blomquist G., Hagman G., Wall A., Ringheim A., Långström B. Nordberg A. (2007) PET imaging of amyloid deposition in patients with mild cognitive impairment. Neurobiol. Aging 29, 1456 1465.
7. Henriksen G., Yousefi B. H., Drzega A. Wester H.-J. (2007) Development and evaluation of compounds for imaging of β-amyloid plaque by means of positron emission tomography. Eur. J. Nucl. Med. Mol. Imaging 35 (Suppl. 1 S75 S81.
8. Hsiao K., Chapman P., Nilsen S., Eckman C., Harigaya S., Yang F. Cole G. (1996) Correlative memory deficits, abeta elevation, and amyloid plaques in transgenic mice. Science 274 (5284 99 102.
9. Ikonomovic M. D., Klunk W. E., Abrahamson E. E. et al. (2008) Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease. Brain 131 (6 1630 1645.
10. Klunk W. E., Wang Y., Huang G. F., Debnath M. L., Holt D. P. Mathis C. A. (2001) Uncharged thioflavin-T derivates bind to amyloid-beta protein with high affinity and readily enter the brain. Life Sci. 69, 1471 1484.
11. Klunk W. E., Engler H., Nordberg A. et al. (2004) Imaging brain amyloid in Alzheimer's disease with Pittsburgh compound-B. Ann. Neurol. 55, 306 319.
12. Klunk W. E., Lopresti B. J., Ikonomovic M. D. et al. (2005) Binding of the positron emission tomography traces Pittsburgh compound-B reflects the amount of amyloid-β in Alzheimer's disease brain but not in transgenic mouse brain. J. Neurosci. 25, 10598 10606.
13. Kudo Y., Okamura N., Furumoto S., Tashiro M., Furukawa K., Maruyama M., Itoh M., Iwata R., Yanai K. Arai H. (2007) 2-(2-[2-dimethylaminothiazol-5-yl] ethenyl)-6-2-[fluoro]ethoxy)benzoxazole: a novel PET agent for in vivo detection of dense amyloid plaques in Alzheimer's disease patients. J. Nucl. Med. 48, 553 561.
14. Lansbury P. T. Lashuel H. A. (2006) A century-old debate on protein aggregation and neurodegeneration enters the clinic Nature 443, 774 779.
15. Lockhart A., Lamb J. R., Osredkar T., Sue L. I., Joyce J. N., Ye L., Libri V., Leppert D. Beach T. G. (2007) PIB is a non-specific imaging marker of amyloid-beta (Aβ) peptide-related cerebral amyloidosis. Brain 130 (Pt 10 2607 2615.
16. Mathis C. A., Lopresti B. J. Klunk W. E. (2007a) Impact of amyloid imaging on drug development in Alzheimers's disease. Nucl. Med. Biol. 34, 809 822.
17. 11C]PIB in Alzheimer's diseas and control subjects. Meeting abstract. J. Nucl. Med. 48 (Suppl. 2 56.
18. Nilsson M. R. (2004) Techniques to study amyloid fibril formation in vitro. Methods 34, 151 160.
19. Nordberg A. (2007) Amyloid imaging in Alzheimer's disease. Curr. Opin. Neurol. 20, 398 402.
20. Paxinos G. Franklin K. B. J. (1997) The Mouse Brain in Stereotaxic Coordinates. Academic Press, San Diego, CA.
21. Pike K. E., Savage S., Villemange V. L., Ng S., Moss S. A., Maruff P., Mathis C. A., Klunk W. E., Masters C. L. Rowe C. C. (2007) β-Amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer's disease. Brain 130, 2837 2844.
22. Rowe C. C., Ackerman U., Browne W. et al. (2008) Imaging of amyloid β in Alzheimer's disease with 18F-BAY94-9172, a novel PET tracer: proof of mechanism. Neurology 7 (2 129 135.
23. 11C]SB-13 PET. Am. J. Geriatr. Psychiatry 12, 584 595.
24. Ye L., Morgenstern J. L., Lamb J. R. Lockhart A. (2006) Characterisation of the binding of amyloid imaging tracers to rodent Aβ fibrils and rodent-human co-polymers. BBRC 347, 669 677.